Clinical trial
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
NCT06683092 is registered in ClinicalTrials.gov with Boston Children's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
- Lead sponsor
- Boston Children's Hospital
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- May 1, 2025
- Completion date
- June 30, 2028
- Enrollment
- 200 (estimated)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.